Research News In Brief
This article was originally published in The Gray Sheet
Myocor: FDA has conditionally approved Myocor's plan for a feasibility study of its iCoapsys minimally invasive mitral valve repair system, the firm announced Dec. 4. The single-arm Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) study will evaluate the device in patients with mitral valve insufficiency caused by left ventricular dysfunction and coronary artery disease. iCoapsys is a high-strength cord, anchored by pads on the outside of the heart, which stretches across the left ventricle to pull the sides of the ventricle together and decrease the distance between the mitral valve leaflets. The device can be delivered with interventional catheters through the pericardium. It is the surgically implanted version of the Coapsys that Myocor is evaluating in the Randomized Evaluation of a Surgical Treatment for Off-pump Repair of the Mitral Valve (RESTOR-MV) trial. RESTOR-MV compares Coapsys to annuloplasty repair in patients undergoing coronary artery bypass surgery who also have functional mitral regurgitation (1"The Gray Sheet" Jan. 3, 2005, p. 17)
You may also be interested in...
Remon Medical Technologies: Waltham, Mass. concern announces close of oversubscribed $26 mil. Series C financing, which will help expand U.S. presence of its wireless, intra-body communication technology for use in therapeutic products. First-time investors in the financing round include Guidant, Triathlon Medical Ventures and Medica Venture Partners. Guidant previously incorporated Remon's interactive sensor technology into its Ancure abdominal aortic aneurysm endograft (1"The Gray Sheet" Feb. 18, 2002, In Brief). Other major Remon financiers include Polaris Venture Partners, Concord Ventures, Lilly Ventures, KBL Healthcare Ventures and Ofer Hi-Tech. The privately held firm intends to commercialize its communication technology through a mixture of internal efforts and external strategic collaborations. Remon is now conducting clinical trials of its Impressure device, which offers an on-demand, non-invasive way to monitor intra-aneurysm pressures after endograft procedures. The firm's HeartLook device for measuring pulmonary artery pressure is also under investigation...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.